Progyny (NASDAQ:PGNY) Stock Gets Price Target Bump from Leerink Partners

Progyny (NASDAQ:PGNY) had its price objective upped by research analysts at Leerink Partners from $37.00 to $38.00 in a research note issued to investors on Thursday, Benzinga reports. The brokerage currently has an “outperform” rating on the stock. Leerink Partners‘s target price would indicate a potential upside of 9.07% from the company’s current price.

A number of other research firms also recently commented on PGNY. Weiss Ratings upgraded shares of Progyny from a “hold (c)” rating to a “hold (c+)” rating in a report on Thursday, October 8th. Barclays decreased their target price on shares of Progyny from $34.00 to $30.00 and set an “equal weight” rating on the stock in a research note on Wednesday, August 12th. Truist Financial boosted their target price on Progyny from $33.00 to $36.00 and gave the stock a “buy” rating in a report on Thursday, August 13th. Jefferies Financial Group set a $33.00 price target on Progyny in a research report on Tuesday, September 8th. Finally, Citigroup reaffirmed a “market outperform” rating on shares of Progyny in a report on Thursday. Eleven analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $34.92.

Progyny Stock Performance

Shares of NASDAQ PGNY traded up $0.47 during mid-day trading on Thursday, reaching $34.84. The company’s stock had a trading volume of 1,548,505 shares, compared to its average volume of 956,940. The stock has a 50-day moving average of $27.45 and a two-hundred day moving average of $24.59. The stock has a market capitalization of $2.67 billion, a P/E ratio of 31.96, a P/E/G ratio of 2.03 and a beta of 0.97. Progyny has a 1-year low of $16.10 and a 1-year high of $35.50.

Progyny (NASDAQ:PGNY) last posted its quarterly earnings results on Wednesday, November 4th. The company reported $0.52 earnings per share for the quarter, topping the consensus estimate of $0.31 by $0.21. The firm had revenue of $341.25 million for the quarter, compared to the consensus estimate of $340.76 million. Progyny had a net margin of 6.00% and a return on equity of 15.98%. The company’s revenue for the quarter was up 8.9% on a year-over-year basis. During the same period last year, the firm posted $0.15 earnings per share. Analysts predict that Progyny will post 1.25 EPS for the current fiscal year.

Insider Activity

In other news, CFO Mark Livingston sold 2,139 shares of the business’s stock in a transaction dated Wednesday, November 4th. The shares were sold at an average price of $30.00, for a total transaction of $64,170.00. Following the transaction, the chief financial officer owned 70,314 shares of the company’s stock, valued at approximately $2,109,420. The trade was a 2.95% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Allison Swartz sold 3,903 shares of the company’s stock in a transaction dated Wednesday, September 23rd. The shares were sold at an average price of $26.10, for a total transaction of $101,868.30. Following the completion of the sale, the executive vice president directly owned 75,816 shares of the company’s stock, valued at $1,978,797.60. This represents a 4.90% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 19,421 shares of company stock worth $539,960. 9.90% of the stock is owned by insiders.

Hedge Funds Weigh In On Progyny

Several institutional investors and hedge funds have recently bought and sold shares of PGNY. BlackRock Inc. acquired a new position in Progyny in the 2nd quarter valued at about $334,426,000. Bank of America Corp DE increased its holdings in shares of Progyny by 75.3% during the 1st quarter. Bank of America Corp DE now owns 1,190,996 shares of the company’s stock worth $20,223,000 after buying an additional 511,609 shares during the last quarter. William Blair Investment Management LLC raised its position in shares of Progyny by 10.7% during the 3rd quarter. William Blair Investment Management LLC now owns 645,130 shares of the company’s stock valued at $16,251,000 after buying an additional 62,178 shares during the period. Principal Financial Group Inc. raised its position in shares of Progyny by 16.4% during the 1st quarter. Principal Financial Group Inc. now owns 554,916 shares of the company’s stock valued at $9,422,000 after buying an additional 78,198 shares during the period. Finally, Danske Bank A S purchased a new stake in shares of Progyny during the 2nd quarter valued at approximately $15,243,000. 94.93% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting Progyny

Here are the key news stories impacting Progyny this week:

• Positive Sentiment: Progyny reported third-quarter earnings of $0.52 per share and revenue of $341.25 million, slightly above the cited consensus revenue estimate. Revenue grew 8.9% year over year, while earnings increased from $0.15 per share a year earlier. Read More.
• Positive Sentiment: The company raised its full-year 2026 earnings guidance, a sign that management sees stronger earnings prospects. Read More.
• Positive Sentiment: Several analysts raised their price targets following the results: Citizens JMP and Leerink Partners moved to $38, while Cantor Fitzgerald raised its target to $35 and maintained an overweight rating. These revisions reinforce a favorable analyst view, although the targets imply varying degrees of potential upside. Read More.
• Neutral Sentiment: Coverage highlighted new client wins and margin expansion, but also noted a cautious market response. This suggests investors may be weighing growth and profitability improvements against expectations already reflected in the stock. Read More.

About Progyny

Progyny, Inc is a benefits-management company focused on fertility and family-building care. The company works with employers to provide comprehensive benefits that help members access fertility treatments and related services through a network of specialized providers.

Its offerings include coverage and support for services such as in vitro fertilization, fertility testing, egg and sperm freezing, donor services, gestational surrogacy, and adoption. Progyny also provides pharmacy benefits through Progyny Rx, as well as personalized guidance intended to help members navigate treatment options, providers, and the broader family-building process.

Progyny primarily serves self-insured employers and their employees in the United States.